Preclinical data with cryopreserved human AML specimens demonstrated in vitro activity across the spectrum of disease stage, cytogenetic risk and CD33 expression levels, leading to the first in human phase I trial in patients with RR/AML (NCT03144245). Here, CD33 is linked to acute myeloid leukemia.